Myasthenia Gravis (MG) Clinical Trials and Treatments

Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction caused by autoantibodies against acetylcholine receptors (AChR) or muscle-specific kinase (MuSK). About 85% of generalized MG patients are AChR-antibody positive, 5-8% are MuSK-positive, and 1-3% have LRP4 antibodies. The remaining patients are classified as seronegative.

The most common symptoms of Myasthenia Gravis include Drooping eyelids (ptosis), Blurred or double vision, Weakness in facial muscles and smile, Difficulty chewing and swallowing, Weakness in arms and legs that worsens with activity, among others. Myasthenia Gravis affects approximately 1 in 5,000 people. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Myasthenia Gravis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Myasthenia gravis treatment options are expanding rapidly with new targeted therapies entering clinical trials. FcRn inhibitors reduce pathogenic antibody levels, while complement inhibitors block the destruction of acetylcholine receptors.

Yes. As of October 14, 2026, 8 FDA-approved medicines have a current label that names Myasthenia Gravis: Imaavy (nipocalimab), first approved in 2025; Rystiggo (rozanolixizumab), first approved in 2023; Soliris (eculizumab), first approved in 2017; Ultomiris (ravulizumab), first approved in 2022; Uplizna (inebilizumab), first approved in 2025; Vyvgart (efgartigimod alfa), first approved in 2021; Zilbrysq (zilucoplan), first approved in 2023; and Mestinon (pyridostigmine bromide). Corticosteroids and immune globulins count once each.

Myasthenia gravis is caused by autoantibodies that attack proteins at the neuromuscular junction, the connection point between nerve and muscle. In AChR-positive MG (85% of generalized cases), antibodies bind to acetylcholine receptors on the muscle surface, triggering complement-mediated destruction and reducing the number of functional receptors. In MuSK-positive MG (5-8%), antibodies target muscle-specific kinase, disrupting the clustering of acetylcholine receptors. The result in both cases is impaired nerve-to-muscle signaling, causing fluctuating weakness that worsens with activity and improves with rest. The thymus gland plays a role in many AChR-positive patients, with thymoma found in about 10-15% and thymic hyperplasia in 60-70% of early-onset cases.

Myasthenia gravis is an autoimmune disease, not a genetic disorder, so standard genetic testing is not used for diagnosis. Instead, antibody testing is the primary diagnostic tool. Approximately 85% of generalized MG patients test positive for acetylcholine receptor (AChR) antibodies, while 5-8% have muscle-specific kinase (MuSK) antibodies, and 1-3% have LRP4 antibodies. The remaining patients are classified as seronegative. Your antibody subtype determines which targeted therapies and clinical trials are available to you. AChR-positive patients have the most trial options, including complement inhibitors and FcRn inhibitors. MuSK-positive patients respond differently to some treatments and have dedicated trial arms. Repetitive nerve stimulation (RNS) and single-fiber electromyography (SFEMG) are electrophysiologic tests used alongside antibody panels.

Eligibility for Myasthenia Gravis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Myasthenia Gravis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.

Myasthenia gravis clinical trials have strict medication washout requirements that vary by drug class. B-cell depleting agents (rituximab, inebilizumab) typically require 6 months. Complement inhibitors (eculizumab, ravulizumab, zilucoplan) need 2 to 4 months. FcRn inhibitors (efgartigimod, rozanolixizumab) generally require 4 weeks. IVIG and plasma exchange usually need a 4-week gap. Trial Friend's medication conflict checker scans each trial's exclusion criteria against common MG medications including cholinesterase inhibitors, corticosteroids, conventional immunosuppressants, targeted therapies, and rescue treatments. The checker flags the specific drug, the trial's exclusion language, and a confidence level so you can discuss timing with your neurologist.

Key questions to ask your neurologist about MG clinical trials include: Are there trials for complement inhibitors or FcRn inhibitors specifically designed for my antibody subtype (AChR-positive vs. MuSK-positive)? Would I need to stop my current B-cell depleting therapy and wait 6 months before enrolling? How do newer targeted therapies compare to my current immunosuppressive regimen in terms of efficacy and side effects? If I use IVIG or plasma exchange for flares, does that disqualify me or just require a 4-week washout? What is my MGFA classification and MG-ADL score, and do I meet the minimum severity threshold for trials I am interested in? Can I continue pyridostigmine and my current immunosuppressant while in a trial?